NCT04210791Enrolling by invitation
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
Source: ClinicalTrials.gov · Last updated 26 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the long-term efficacy and prognosis risk factors of autologous stem cell transplantation for the treatment of AL amyloidosis.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 14 Dec 2019
- Start date
- 1 Jul 2010
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Nanjing University School of Medicine
- Diseases
- Amyloidosis
- NCT number
- NCT04210791
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jul 2010 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- hypersensitivity to any treatment drugs;
- Subjects have severe cardiovascular disease;
- Subjects have a serious physical disease and mental illnesses;
- Other conditions that researchers consider are not suitable for transplantation.
Other
- Pregnant and breastfeeding women;
- Subjects suffering from multiple myeloma;
Who the study is looking for
- Male or female;
- aged 18-75 years;
- Patients with newly diagnosed AL;
- Appropriate for autologous hematopoietic stem cell transplantation;
- Abnormal M protein or free light chain detected in serum and/or urine
- ECOG score 0-2 points;
- Subjects (or their legal representatives) must sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Clinical Research Center of Kidney Diseases, Jinling Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.